JP2023530039A5 - - Google Patents

Info

Publication number
JP2023530039A5
JP2023530039A5 JP2023519161A JP2023519161A JP2023530039A5 JP 2023530039 A5 JP2023530039 A5 JP 2023530039A5 JP 2023519161 A JP2023519161 A JP 2023519161A JP 2023519161 A JP2023519161 A JP 2023519161A JP 2023530039 A5 JP2023530039 A5 JP 2023530039A5
Authority
JP
Japan
Prior art keywords
nme7
sequence
cancer
cells
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023519161A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023530039A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/036500 external-priority patent/WO2021252551A2/en
Publication of JP2023530039A publication Critical patent/JP2023530039A/ja
Publication of JP2023530039A5 publication Critical patent/JP2023530039A5/ja
Pending legal-status Critical Current

Links

JP2023519161A 2020-06-08 2021-06-08 抗ｎｍｅ抗体および癌または癌転移の治療方法 Pending JP2023530039A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063036288P 2020-06-08 2020-06-08
US63/036,288 2020-06-08
US202063044670P 2020-06-26 2020-06-26
US63/044,670 2020-06-26
US202063046852P 2020-07-01 2020-07-01
US63/046,852 2020-07-01
PCT/US2021/036500 WO2021252551A2 (en) 2020-06-08 2021-06-08 Anti-nme antibody and method of treating cancer or cancer metastasis

Publications (2)

Publication Number Publication Date
JP2023530039A JP2023530039A (ja) 2023-07-12
JP2023530039A5 true JP2023530039A5 (cg-RX-API-DMAC7.html) 2024-06-19

Family

ID=78845867

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023519161A Pending JP2023530039A (ja) 2020-06-08 2021-06-08 抗ｎｍｅ抗体および癌または癌転移の治療方法

Country Status (9)

Country Link
US (1) US12049514B2 (cg-RX-API-DMAC7.html)
EP (1) EP4161970A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023530039A (cg-RX-API-DMAC7.html)
KR (1) KR20230021699A (cg-RX-API-DMAC7.html)
CN (1) CN116367857A (cg-RX-API-DMAC7.html)
AU (1) AU2021289677A1 (cg-RX-API-DMAC7.html)
CA (1) CA3181655A1 (cg-RX-API-DMAC7.html)
IL (1) IL298780A (cg-RX-API-DMAC7.html)
WO (1) WO2021252551A2 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015243948B2 (en) 2014-04-07 2020-10-15 Minerva Biotechnologies Corporation Anti-NME antibody
EP3920693A4 (en) 2019-02-04 2022-10-05 Minerva Biotechnologies Corporation ANTI-NME ANTIBODIES AND METHODS OF TREATMENT OF CANCER OR CANCER METASTASIS
EP4161970A4 (en) * 2020-06-08 2024-07-10 Minerva Biotechnologies Corporation ANTI-NME ANTIBODIES AND METHODS FOR TREATING CANCER OR CANCER METASTASES
CA3183682A1 (en) 2020-06-26 2021-12-30 Minerva Biotechnologies Corporation Anti-nme antibody and method of treating cancer or cancer metastasis
CN119317447A (zh) 2022-04-12 2025-01-14 米纳瓦生物技术公司 抗可变muc1*抗体及其用途

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5631271A (en) 1986-11-29 1997-05-20 Serfontein; Willem J. Methods and preparations for the treatment and prophylaxis of metabolic disturbances
US5874285A (en) 1996-09-13 1999-02-23 Incyte Pharmaceuticals, Inc. Polynucleotide encoding a novel human nm23-like protein
US6818749B1 (en) 1998-10-31 2004-11-16 The United States Of America As Represented By The Department Of Health And Human Services Variants of humanized anti carcinoma monoclonal antibody cc49
CA2384713A1 (en) 1999-09-29 2001-04-05 Human Genome Sciences, Inc. Colon and colon cancer associated polynucleotides and polypeptides
CA2491017A1 (en) 2002-07-03 2004-01-15 Immunogen, Inc. Antibodies to non-shed muc1 and muc16, and uses thereof
AU2003299643A1 (en) 2002-12-04 2004-06-23 Diadexus, Inc. Compositions, splice variants and methods relating to colon specific genes and proteins
ES2624863T3 (es) 2005-06-08 2017-07-17 Millennium Pharmaceuticals, Inc. Métodos para identificación, evaluación, y tratamiento de pacientes con terapia de cáncer
US20100254996A1 (en) 2007-06-18 2010-10-07 Medimmune, Llc Synergistic treatment of cells that express epha2 and erbb2
DK2334703T3 (en) 2008-09-17 2015-10-05 Innate Pharma Configurations and methods for detection of tlr3
EP3130607B1 (en) 2008-10-06 2024-04-17 Minerva Biotechnologies Corporation Muc1* antibodies
WO2010042760A2 (en) 2008-10-08 2010-04-15 The Administrators Of The Tulane Educational Fund Compositions, methods, and kits for enhancing the immunogenicity of pathogenic antigens
MX2011013385A (es) 2009-06-11 2012-05-29 Minerva Biotechnologies Corp Metodos para cultivar celulas madre y celulas progenitoras.
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
CN109456932A (zh) 2011-10-17 2019-03-12 米纳瓦生物技术公司 用于干细胞增殖和诱导的培养基
AU2013222935B2 (en) 2012-02-24 2016-03-10 Alteogen Inc. Modified antibody in which motif comprising cysteine residue is bound, modified antibody-drug conjugate comprising the modified antibody, and production method for same
WO2013151665A2 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins associated with human disease
WO2014018679A2 (en) 2012-07-24 2014-01-30 Minerva Biotechnologies Corporation Nme variant species expression and suppression
WO2014028668A2 (en) 2012-08-14 2014-02-20 Minerva Biotechnologies Corporation Stem cell enhancing therapeutics
CA2886161A1 (en) 2012-09-29 2014-04-03 The Trustees Of The University Of Pennsylvania Veterinary composition and methods for non-surgical neutering and castration
US20160326263A1 (en) 2013-02-20 2016-11-10 Minerva Biotechnologies Corporation NME Inhibitors and Methods of Using NME Inhibitors
CA2901893C (en) 2013-02-20 2022-08-30 Minerva Biotechnologies Corporation Nme inhibitors and methods of using nme inhibitors
AU2015243948B2 (en) 2014-04-07 2020-10-15 Minerva Biotechnologies Corporation Anti-NME antibody
CN116199790A (zh) * 2015-02-10 2023-06-02 米纳瓦生物技术公司 人源化抗MUCl*抗体
CN105384825B (zh) 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
CN108409862B (zh) * 2016-07-14 2021-07-13 中国科学院生物物理研究所 I型干扰素受体抗体及其用途
WO2018054240A1 (en) * 2016-09-20 2018-03-29 Wuxi Biologics (Shanghai) Co. Ltd. Novel anti-pcsk9 antibodies
CA3039797A1 (en) 2016-10-11 2018-04-19 Minerva Biotechnologies Corporation Humanized anti-muc1* antibodies and use of cleavage enzyme
WO2019104306A1 (en) * 2017-11-27 2019-05-31 Minerva Biotechnologies Corporation Humanized anti-muc1* antibodies and direct use of cleavage enzyme
EP3920693A4 (en) 2019-02-04 2022-10-05 Minerva Biotechnologies Corporation ANTI-NME ANTIBODIES AND METHODS OF TREATMENT OF CANCER OR CANCER METASTASIS
EP4161970A4 (en) * 2020-06-08 2024-07-10 Minerva Biotechnologies Corporation ANTI-NME ANTIBODIES AND METHODS FOR TREATING CANCER OR CANCER METASTASES
CA3183682A1 (en) 2020-06-26 2021-12-30 Minerva Biotechnologies Corporation Anti-nme antibody and method of treating cancer or cancer metastasis

Similar Documents

Publication Publication Date Title
JP7695193B2 (ja) 抗ｎｍｅ抗体および癌または癌転移の治療方法
US12479928B2 (en) Anti-cancer peptide
US12415868B1 (en) Anti-NME antibody and method of treating cancer or cancer metastasis
JP2023530039A5 (cg-RX-API-DMAC7.html)
JP2023532293A5 (cg-RX-API-DMAC7.html)
US12049514B2 (en) Anti-NME antibody and method of treating cancer or cancer metastasis
HK40101426A (zh) 抗nme抗体及治疗癌症或癌症转移的方法
HK40094150A (zh) 抗nme抗体及治疗癌症或癌症转移的方法
AU2026202696A1 (en) Anti-NME antibody and method of treating cancer or cancer metastasis
HK40064429B (zh) 抗nme抗体及治疗癌症或癌症转移的方法
HK40064429A (en) Anti-nme antibody and method of treating cancer or cancer metastasis